Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES

BACKGROUND: Chronic kidney disease (CKD) was a relative contraindication to HCV treatment in the interferon/ribavirin era due to poor tolerability and lower efficacy. Our aim was to determine the effectiveness treatment completion, and safety of sofosbuvir/ledipasvir (SOF/LDV) and paritaprevir/riton...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Adeel, Ren, Yanjie, Puenpatom, Amy, Arduino, Jean Marie, Kumar, Ritesh, Abou-Samra, Abdul-Badi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632024/
http://dx.doi.org/10.1093/ofid/ofx163.376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632024/
http://dx.doi.org/10.1093/ofid/ofx163.376

Ejemplares similares